深圳市亚辉龙生物科技股份有限公司关于自愿披露签署战略合作框架协议的公告

Core Viewpoint - Shenzhen Yahui Long Biotechnology Co., Ltd. has signed a strategic cooperation framework agreement with Shenzhen Brain Machine Star Chain Technology Co., Ltd. The agreement is a framework and does not involve specific monetary commitments, with further details to be clarified in future collaborations [2][12]. Group 1: Agreement Overview - The strategic cooperation agreement was signed on January 6, 2026, in Shenzhen and is a written document [3]. - The agreement is a non-binding framework that does not require approval from the company's board or shareholders [5]. - The cooperation aims to leverage Yahui Long's strong sales channels and expert resources in emergency care and brain disease diagnosis, combined with Brain Machine Star Chain's advanced technology and R&D capabilities in brain-machine interface [6][13]. Group 2: Cooperation Content - The cooperation will focus on market expansion and sales support for Brain Machine Star Chain's existing and in-development products through Yahui Long's sales channels [6]. - Joint R&D efforts will be enhanced, particularly in areas such as stroke, neurodegenerative diseases, and pediatric conditions, to accelerate product development and clinical processes [6][13]. - Both parties agree to prioritize each other for capital and equity cooperation under equal conditions, aiming to improve financing efficiency and governance for Brain Machine Star Chain [6]. Group 3: Rights and Obligations - Yahui Long will provide necessary academic and expert resources to support the R&D and market promotion of the products [7]. - Brain Machine Star Chain is responsible for supplying competitive products that meet national medical device regulations and supporting Yahui Long's marketing activities [9]. - Both parties will maintain communication and share resources while adhering to national laws and regulations [10]. Group 4: Impact on Company - The strategic cooperation agreement is expected to have no significant impact on Yahui Long's current year operating performance, with future impacts dependent on the progress of specific projects [12]. - The collaboration is anticipated to enhance Yahui Long's competitiveness in central nervous system diseases and expand its strategic layout in the brain-machine interface sector, aligning with the company's long-term development strategy [13].